Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Volume 59(3); 2026 > Article
Review Updated bowel preparation regimens for colonoscopy: benefits and drawbacks
Seung Min Hongorcid, Dong Hoon Baekorcid
Clinical Endoscopy 2026;59(3):345-355.
DOI: https://doi.org/10.5946/ce.2025.201
Published online: December 18, 2025

Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea

Correspondence: Dong Hoon Baek Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea E-mail: dhbeak77@gmail.com
• Received: June 26, 2025   • Revised: July 19, 2025   • Accepted: July 20, 2025

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 12,715 Views
  • 496 Download
  • 3 Web of Science
  • 6 Crossref
  • 4 Scopus
prev next
  • Optimal bowel preparation is critical for high-quality colonoscopy and the effective prevention of colorectal cancer. Although traditional high-volume polyethylene glycol (PEG) electrolyte lavage solutions are effective and safe, they are frequently limited by poor patient tolerability. To improve adherence, several low- and ultra-low-volume PEG-based regimens, particularly 2 L and 1 L PEG plus ascorbate, have demonstrated noninferior efficacy and better patient compliance. Hyperosmotic alternatives, including oral sulfate solution and sodium picosulfate with magnesium citrate, provide comparable bowel-cleansing efficacy and are often favored for their improved palatability and tolerability. The recent introduction of oral sulfate tablets offers the convenience of a tablet form while maintaining efficacy similar to that of PEG-based regimens and significantly enhancing tolerability. However, a few cases of gastric mucosal irritation have been reported. Adjunctive simethicone also improves mucosal visibility by reducing intraluminal bubbles. With the growing diversity of bowel preparation options, regimen selection should be tailored to individual patient characteristics, including age, comorbidities, prior experiences, and personal preferences. A personalized evidence-based approach, guided by patient-specific factors and supported by emerging clinical data, can improve adherence, ensure adequate bowel cleansing, and enhance the diagnostic yield and procedural efficiency of colonoscopy.
Colorectal cancer (CRC) remains a major global health concern due to its high mortality rate and substantial socioeconomic burden. Despite advances in screening and treatment, CRC remains one of the leading causes of cancer-related deaths worldwide. CRC poses a significant public health burden in Korea, with a crude prevalence of 569.8 per 100,000 in 2020.1 The steady rise in the incidence, from 45.4 per 100,000 in 2006 to 54.5 in 2014, mirrors global trends and underscores the need for effective screening strategies, including high-quality colonoscopy. Globally, the burden is projected to increase to 3.2 million new cases by 2040.2 Colonoscopy is the gold standard for the early detection and prevention of CRC, enabling both the diagnostic assessment and removal of precancerous lesions in a single procedure. It has been shown to significantly reduce both the CRC incidence and mortality.3,4 However, the effectiveness of colonoscopy is highly dependent on bowel preparation quality.
The quality of colonoscopy is commonly assessed using objective indicators such as the adenoma detection rate and cecal intubation rate.5 While these metrics are influenced by endoscopist performance, high-quality bowel preparation is an equally essential determinant. Currently, no standardized approach exists for bowel preparation, with multiple available lavage agents that differ in efficacy, safety, palatability, and cost-effectiveness. In addition, the timing of purgative administration varies, with the split-dose regimen, typically halving the dose the evening before and the remainder on the morning of the procedure, which is the most widely recommended method for optimal bowel preparation.6,7
Inadequate bowel preparation (occurring in up to ±25% of colonoscopies) is associated with reduced detection of polyps and adenomas, prolonged procedure times, and the need for earlier repeat examinations (Table 1).6-9 Recognizing this, expert consensus guidelines now emphasize achieving ≥90% adequacy in bowel prep as a key quality benchmark.6,7 An ideal bowel preparation agent should consistently clear more than 90% of the mucosal surface while remaining safe, well-tolerated, and acceptable to patients.6,7 However, poor patient compliance with traditional high-volume preparations has long represented a major barrier.10 In recent years, several new bowel preparation agents and formulations have been introduced to improve patient experience without compromising efficacy. These include low-volume or ultra-low-volume polyethylene glycol (PEG)-based solutions, sulfate-based preparations, and combination regimens incorporating osmotic and stimulant laxative mechanisms. This review classifies new bowel preparation regimens by their mechanism of action, summarizes their benefits and drawbacks (efficacy, safety, tolerability, patient adherence, and cost), and compares recent evidence. A summary of these agents and their key characteristics is provided in Table 2.
Bowel preparation regimens exert their effects through two primary pharmacologic mechanisms: osmotic action, which promotes fluid retention within the intestinal lumen, and stimulant action, which increases colonic motility. Many modern preparations combine these two mechanisms to enhance efficacy and patient tolerability. Bowel preparation regimens are commonly classified according to the total volume of purgative administered. High-volume regimens, typically consisting of 4 liters of solution, may be administered as day-before, same-day, or split-dose protocols, a strategy often referred to as “full-volume” in the literature. Low-volume regimens (2 to <4 L) and ultra-low-volume regimens (<2 L) can also be delivered using similar timing formats, with ultra-low-volume strategies generally favored for same-day or split-dose administration owing to improved tolerability. The following sections summarize the major regimen categories and highlight key examples of newly approved or recently investigated agents within each class.
Osmotic laxatives

1) Isosmotic agents

(1) PEG-electrolyte lavage solution: mechanism, efficacy, and clinical considerations

Osmotic laxatives are the cornerstone of bowel preparation and exert their effects by drawing water into the intestinal lumen to facilitate colonic cleansing. Among these agents, PEG-electrolyte lavage solution (PEG-ELS) has long been regarded as the standard preparation because of its isotonic composition and negligible systemic absorption.11 High-volume PEG regimens (4 L) are United States (US) Food and Drug Administration (FDA)-approved and are considered highly effective and safe across a broad spectrum of patients, including those with renal insufficiency or congestive heart failure (CHF). However, the large fluid volume and unpalatable taste often compromise patient adherence, with reported discontinuation rates ranging from 5% to 15%.12 Common adverse effects associated with high-volume PEG-based bowel preparation regimens include abdominal bloating, cramping, nausea, vomiting, and insomnia. These volume-related side effects may be alleviated by reducing the total purgative volume.
To improve tolerability and patient adherence, several low-volume PEG-based bowel preparation regimens have been developed that incorporate hyperosmotic adjuncts such as ascorbic acid, citrate, or simethicone. Representative examples include 2 L PEG plus ascorbate formulations and ultra-low-volume 1 L PEG plus ascorbate regimens, both of which are US FDA-approved and have demonstrated noninferior bowel preparation efficacy with improved patient acceptability compared to traditional 4 L PEG-ELS protocols.6 However, it is important to note that the term “low-volume” refers specifically to the purgative solution and does not account for the additional water intake (typically 1–2 L) required to ensure adequate hydration and colonic flushing.
A novel 2 L PEG-based formulation containing citrate and simethicone was approved by the US FDA. Citrate enhances both palatability and osmotic activity, whereas simethicone minimizes intraluminal foam formation, collectively improving bowel preparation and patient tolerability. In a multicenter randomized trial comparing 2 L PEG/citrate to 4 L PEG-ELS, both regimens demonstrated comparable overall bowel preparation success rates (73.6% vs. 72.3%), but the PEG/citrate group showed significantly better tolerability (72.8% vs. 63.0%, p=0.0314) and greater willingness to reuse (93.9% vs. 82.2%, p=0.0002), with similar compliance rates (91.1% vs. 90.9%) and no serious adverse events reported.13 Another trial comparing 2 L PEG/citrate with 2 L PEG/ascorbate showed no significant differences in bowel preparation efficacy (78.3% vs. 74.3%, p=0.37), patient-reported tolerability (81.4% vs. 80.8%, p=0.74), or the incidence of mild adverse effects.14 Despite these favorable outcomes, the hyperosmolar nature of citrate raises concerns regarding potential electrolyte disturbances and dehydration, warranting caution in patients with severe renal impairment.
Additionally, a low-volume regimen combining 2 L of PEG with bisacodyl has been investigated as an alternative to traditional high-volume preparations. Recent meta-analyses and randomized controlled trials (RCTs) support the non-inferiority of low-volume regimens compared to that of high-volume PEG in terms of bowel preparation efficacy, while also demonstrating superior patient tolerability. For example, a large RCT (n=2,314) comparing 4 L split-dose PEG with 2 L split-dose PEG plus bisacodyl found no clinically meaningful difference in bowel preparation adequacy (90% vs. 89%, p=0.02), although patient willingness to repeat the regimen was significantly higher in the low-volume group (91.9% vs. 66.9%, p<0.01).15 However, rare instances of ischemic colitis have been reported,16 leading to the revocation of US FDA approval for bisacodyl-containing bowel preparation products in 2011.
The most recent development in this category is NER1006, an ultra-low-volume (1 L) PEG plus ascorbate formulation. Although it has been shown to provide noninferior bowel preparation efficacy compared to standard 2 to 4 L PEG regimens, a meta-analysis including ten trials (n=1,717) reported an adequate bowel preparation rate of 83%, which was somewhat lower than that observed with other low-volume regimens. Importantly, all regimens included in the meta-analysis were administered using a split-dose protocol, reinforcing the critical importance of dosing timing in achieving successful bowel preparation.17 Another ultra-low-volume strategy currently under investigation involves combining 1 L PEG with linaclotide, a guanylate cyclase-C agonist with both secretory and pro-motility properties. In a recent RCT involving 548 patients who underwent afternoon colonoscopies, the 1 L PEG plus linaclotide regimen achieved a bowel preparation adequacy rate of 90.5%, compared to 91.6% in the 2 L PEG group (p=0.64).18 Moreover, the lower-volume regimen was associated with fewer adverse effects and greater patient willingness to repeat the preparation (95.2% vs. 82.2%, p<0.01).
However, not all ultra-low-volume regimens have consistently demonstrated satisfactory outcomes. A meta-analysis evaluating regimens with volumes <1 L reported suboptimal bowel preparation adequacy rates for sodium picosulfate/magnesium citrate (SPMC) (75%) and sodium phosphate (<1 L, 82%).17 Moreover, specific safety considerations apply to certain patient populations when using low-volume PEG regimens. Aspartame, which is included in some formulations as a flavoring agent, is metabolized to phenylalanine and should be avoided in individuals with phenylketonuria. Ascorbate, a commonly used hyperosmotic adjunct, may induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and should be used cautiously in individuals with severe renal impairment (creatinine clearance <30 mL/min) or New York Heart Association class III or IV CHF.19,20 In addition, hypernatremia may occur because of the sodium content in certain formulations; therefore, adequate fluid intake is strongly recommended during the bowel preparation process.7

2) Hyperosmotic agents

(1) Oral Sulfate Solution: Mechanism, Efficacy, and Clinical Considerations

Oral sulfate solutions (OSS) are hyperosmotic laxatives composed of a trisulfate formulation that includes sodium sulfate, potassium sulfate, and magnesium sulfate, with sodium sulfate serving as the predominant active component. These non-absorbable anions exert their effects by retaining water within the intestinal lumen, thereby facilitating effective bowel preparation. Owing to their minimal intestinal absorption and absence of significant systemic electrolyte shifts, OSS is theoretically considered safe with respect to fluid and electrolyte balance. OSS has been approved by the US FDA for split-dose use only. The typical regimen involves approximately 1 L of OSS solution and 2 L of water (total intake ±3 L).
OSS has been shown to provide superior or comparable bowel preparation efficacy compared to high- and low-volume PEG-based regimens. An RCT demonstrated that split-dose OSS yielded significantly better bowel preparation outcomes compared to 4 L Sulfate-Free PEG-ELS (98.4% vs. 89.6%, p=0.04), with similar safety profiles.21 In a meta-analysis of seven studies (n=2,049),22 OSS demonstrated similar bowel preparation efficacy to low-volume PEG-ascorbate regimens, but was associated with a higher incidence of nausea (relative risk [RR], 1.35; 95% confidence interval [CI], 1.03–1.77) and vomiting (RR, 2.30; 95% CI, 1.63–2.23). Notably, OSS was associated with an increased adenoma detection rate compared to 2 L PEG-ELS (odds ratio, 1.17; 95% CI, 1.03–1.33).23 Further, a prospective comparative study evaluating OSS and SPMC demonstrated that OSS had significantly higher rates of adequate bowel preparation (94.7% vs. 85.7%, p=0.006) and excellent bowel preparation (54% vs. 26%, p<0.001). However, no significant difference was observed in the overall preparation adequacy (96.3% vs. 94.9%, p=0.614), and patients in the SPMC group reported superior taste and tolerability.24
Despite these benefits, OSS should be used with caution when selecting patients. Patients with CHF, ascites, or severe renal impairment (creatinine clearance <30 mL/min) are generally advised to avoid OSS because of the potential risks of dehydration and fluid-electrolyte imbalance. Although severe adverse events, such as acute kidney injury, have been infrequently reported, maintaining adequate hydration during administration is essential. In addition, transient elevations in serum uric acid levels were observed, warranting caution in patients with a history of gout.25

(2) Oral Sulfate Tablets: Mechanism, Efficacy, and Clinical Considerations

Oral sulfate tablets (OSTs) have been developed as a convenient, solid-form alternative to the traditional OSS- and PEG-based regimens. The conventional OST formulation has been approved by the US FDA. It contains a combination of sodium sulfate, potassium sulfate, and magnesium sulfate and exerts its bowel preparation effect via an osmotic mechanism by drawing water into the intestinal lumen. The tablets are administered using a split-dose regimen, requiring the ingestion of 14 large tablets with 1 liter of water on two occasions (28 tablets in total). Importantly, OSTs (Orafang; Pharmbio Korea Co.) contain simethicone, an anti-foaming agent that reduces intraluminal bubbles and enhances mucosal visibility during colonoscopy.26
OSTs have consistently demonstrated effective and reliable bowel preparation in various clinical settings. In a multicenter RCT, OSTs showed noninferior bowel preparation efficacy compared to the 2 L PEG plus ascorbate regimen. Moreover, OSTs achieved a significantly higher mean Boston Bowel Preparation Scale score (8.2 vs. 7.8, p=0.04) and a greater proportion of high-quality bowel preparation across all colonic segments.26 In a separate study comparing OSTs with the 1 L PEG plus ascorbate regimen, both regimens met the American Gastroenterological Association adequacy criteria (>95%), but OSTs exhibited a trend toward improved adenoma detection (59.6% vs. 41.9%) and significantly improved mucosal visibility as measured by the bubble score (p<0.001).27 In a large retrospective study (n=16,971), OST use was associated with a significantly higher adenoma detection rate compared to PEG-A use (34.5% vs. 30.7%, p<0.001), especially in the right colon (13.5% vs. 11.2%, p<0.001). Although nausea was more frequent with OSTs (3.08% vs. 1.47%), insufficient intake was less common, suggesting good overall tolerability.28
The safety profile of OSTs is consistently favorable across various patient populations. Among older adults (aged ≥70 years), OSTs not only resulted in significantly higher rates of high-quality bowel preparation (55.7% vs. 28.4%, p<0.001) and adenoma detection (54.8% vs. 35.3%, p=0.003), but also exhibited a favorable safety profile, with no serious adverse events reported.29 In patients with inflammatory bowel disease (IBD), OSTs have been shown to be both safe and effective, with no serious adverse events or disease exacerbations reported during the bowel preparation process.30 Similarly, in the setting of preoperative bowel preparation for CRC surgery, OST use did not increase the incidence of surgical site infections.31
Although OSTs have demonstrated consistent efficacy and an overall favorable safety profile across various clinical settings, recent reports have raised concerns about their potential to induce gastric mucosal injury. In a prospective study employing concurrent esophagogastroduodenoscopy, gastric erythema, edema, and hemorrhagic erosions were observed in 82% of patients who received OSTs, compared to 28% in those receiving OSS and 19% in patients who underwent PEG-based regimens (p<0.0001).32 These lesions primarily involved the greater curvature of the gastric body and occurred independently of non-steroidal anti-inflammatory drug use or Helicobacter pylori infection. Even though most patients were asymptomatic, some experienced epigastric discomfort or developed anemia. Ensuring adequate hydration and extending dosing intervals may help reduce mucosal irritation. Large-scale trials have not reported significant electrolyte abnormalities with OSTs; however, rare clinical cases of hyponatremia or neurological symptoms, such as confusion or seizure-like episodes, have been observed in real-world settings. Clinicians should accordingly monitor at-risk patients, especially older adults or those with baseline electrolyte disturbances.33

3) Sodium picosulfate and magnesium citrate

SPMC is a dual-action bowel preparation regimen that combines an osmotic laxative (magnesium citrate) with a stimulant laxative (sodium picosulfate). Sodium picosulfate is a prodrug metabolized by colonic bacteria into its active form, desacetyl bisacodyl, which stimulates colonic peristalsis. This combination achieves effective bowel preparation while maintaining a relatively low total fluid volume. The regimen typically consists of approximately 300 mL of reconstituted SPMC solution, followed by at least 2 L of additional clear fluids, resulting in a total fluid intake of approximately 2.5 to 3 L.
SPMC has demonstrated high bowel preparation efficacy and superior patient tolerability compared with high-volume PEG-based regimens. In a meta-analysis of 25 RCTs, SPMC showed noninferior bowel-cleansing efficacy compared to PEG, with a RR of 0.93 (95% CI, 0.86–1.01; p=0.07), retaining over 90% of PEG’s cleansing effectiveness. There were no significant differences in polyp detection rate (RR, 0.94; 95% CI, 0.82–1.08) or adenoma detection rate (RR, 0.88; 95% CI, 0.74–1.05) between the two groups. However, patient tolerability outcomes favored SPMC, with higher regimen completion rates (RR, 1.08; 95% CI, 1.04–1.13; p<0.001) and greater willingness to reuse the regimen (RR, 1.44; 95% CI, 1.25–1.67; p<0.001). The overall incidence of adverse events was significantly lower with SPMC (RR, 0.78; 95% CI, 0.66–0.93; p=0.004).34 In a more recent meta-analysis of 13 RCTs, SPMC demonstrated slightly superior bowel preparation efficacy compared to PEG (RR, 1.06; 95% CI, 1.02–1.11).35 SPMC was significantly better tolerated than PEG in most included trials, and no significant differences in bowel preparation efficacy or tolerability were observed between SPMC and sodium phosphate. Regarding specific adverse events, dizziness was more commonly reported with SPMC than with PEG (RR, 1.71; 95% CI, 1.32–2.21), while vomiting occurred less frequently with single-dose SPMC regimens than with split-dose regimens (RR, 0.35; 95% CI, 0.13–0.95). Several RCTs conducted in Korea compared SPMC with 2 L PEG plus ascorbate, demonstrating comparable bowel preparation efficacy but superior patient-reported outcomes in the SPMC group.36-38 In one study, SPMC was associated with a lower incidence of adverse effects, including nausea, vomiting, and abdominal discomfort (47.4% vs. 62.4%, p=0.031), as well as significantly higher tolerability ratings (92.1% vs. 83.4%, p=0.001).38 In addition, patients receiving SPMC consistently rated it more favorably in terms of taste and overall satisfaction compared with PEG-based regimens.
Despite its advantages, SPMC is not without safety concerns. Due to its hyperosmolar nature, it is contraindicated in patients with severe renal impairment, CHF, or hypermagnesemia.39 While serum magnesium levels typically normalize rapidly in individuals with normal renal function, hyponatremia has been reported in older adults, with an absolute risk increase of 0.05% and a RR of 2.4 (95% CI, 1.5–3.9).40 In rare cases, improper dissolution of powdered SPMC formulations has resulted in esophageal or gastric injury, highlighting the importance of adequate reconstitution and ingestion with sufficient fluids.41 The introduction of ready-to-drink liquid formulations has mitigated this risk and enhanced ease of administration.42
Modern bowel preparation regimens, including PEG-based solutions (high-, low-, and ultra-low-volume), OSS, OST, and SPMC, have shown variable efficacy, tolerability, and safety across populations. Low- and ultra-low-volume PEG with ascorbate and OST demonstrated favorable patient adherence. OSS and SPMC are equally effective, but require caution in patients with renal or cardiac comorbidities. Understanding the unique mechanisms and safety profiles of each agent is essential for tailoring regimens for individual patients.
The expanding range of available bowel preparation options allows clinicians to individualize regimens based on each patient’s clinical characteristics, preferences, and risk factors. Contemporary clinical guidelines emphasize this patient-centered approach, acknowledging that personalized regimen selection enhances not only the efficacy of bowel preparation but also patient adherence and the overall success of colonoscopic procedures.
Efficacy versus tolerability
Although newer bowel preparation agents have demonstrated high efficacy in clinical trials, their real-world effectiveness is closely associated with patient tolerability and compliance. Adverse experiences during ingestion, such as nausea, vomiting, and abdominal discomfort, often determine whether a patient can complete the prescribed regimen. Therefore, clinicians should carefully evaluate prior patient experience with bowel preparation when selecting an appropriate regimen. For example, patients who have previously experienced nausea or vomiting with liquid purgatives may benefit from tablet-based formulations. Conversely, patients who have difficulty tolerating the total volume of traditional regimens may be better suited for ultra-low-volume options, such as 1 L PEG with ascorbate or low-volume picosulfate-based preparations.
Patient age and comorbidities
Age and comorbidities are important factors that influence both the safety and efficacy of bowel preparation regimens. Older adults, particularly those aged ≥70 years, are at increased risk for fluid and electrolyte disturbances, necessitating careful regimen selection. Therefore, SPMC should be used with caution in this population due to its potential to induce hyponatremia. In contrast, PEG-based preparations, particularly iso-osmotic 4 L PEG-ELS or low-volume PEG-electrolyte formulations, are generally regarded as safer alternatives for older adults.
Patients with significant comorbidities require special attention
In patients with chronic kidney disease (estimated glomerular filtration rate <30 mL/min/1.73 m²), hyperosmotic agents such as OSS and SPMC should be avoided due to the potential risks of electrolyte imbalance and dehydration. Iso-osmotic PEG-based regimens, particularly 4 L PEG-ELS, are considered the safest options for this population.
Patients with CHF are particularly vulnerable to fluid and electrolyte shifts. In this group, PEG-based regimens are the preferred option, whereas sulfate- or phosphate-containing agents should generally be avoided to minimize cardiovascular risk.
In patients with liver cirrhosis and ascites, bowel preparation can exacerbate fluid retention and disrupt serum electrolyte balance. PEG-ELS, which avoids abrupt osmotic shifts, is generally considered to be the safest option for this population.
Younger, medically stable individuals without significant comorbidities can generally tolerate any of the currently available bowel preparation regimens. In such cases, personal preferences, such as aversion to liquid formulations or difficulty swallowing tablets, can be prioritized to enhance compliance and overall patient satisfaction.
Specific contraindications and high-risk populations
Several clinical scenarios necessitate the avoidance of specific components in bowel preparation regimens: (1) Ascorbate-containing preparations are contraindicated in patients with G6PD deficiency owing to the risk of hemolytic anemia; (2) Flavored preparations that contain phenylalanine should be avoided in individuals with phenylketonuria; (3) Sulfate-based agents may elevate serum uric acid levels and are, therefore, suboptimal for patients with a history of gout; (4) Tablet-based regimens may be unsuitable for patients with dysphagia or those who have undergone bariatric or upper gastrointestinal surgery, due to concerns regarding gastric retention and excessive pill burden; (5) Although colonoscopy is rarely indicated during pregnancy, it may be necessary in certain clinical situations. In such cases, PEG-based regimens are considered the safest option; however, hyperosmotic or stimulant-containing agents should be avoided because of their potential for uterine stimulation and electrolyte imbalances; (6) Patients with IBD, particularly those with active disease, benefit from PEG-based regimens. OSTs have also been shown to be safe in this population, with no increased risk of flares. In patients with IBD, particularly during active disease, PEG-based preparations are preferred because of their gentle action, and OSTs have demonstrated safety without an increased risk of disease flares.
These contraindications underscore the importance of obtaining a comprehensive medical history before selecting an appropriate bowel preparation regimen.
In summary, the optimal bowel preparation selection should be guided by a comprehensive assessment of patient age, comorbidities, prior experience with bowel preparation, personal preferences, and risk factors for complications. By integrating these considerations, clinicians can tailor bowel preparation regimens for individual patients, thereby enhancing patient adherence and improving colonoscopic outcomes. Personalized preparation strategies not only optimize mucosal visualization and adenoma detection but also enhance safety and patient satisfaction. In the context of precision medicine and shared decision making, a patient-centered approach to bowel preparation has become a fundamental component of high-quality colonoscopic care (Table 3).
In addition to selecting the appropriate bowel preparation regimen, adjunctive agents play a complementary role in optimizing the bowel preparation quality and procedural outcomes. Among these, simethicone is the only adjunct, supported by moderate-quality evidence, particularly for reducing intraluminal foam and enhancing mucosal visibility. A meta-analysis and several RCTs have shown that adding simethicone to PEG-based regimens significantly improves bowel cleanliness, BBPS scores, and adenoma detection rates.43 While the optimal timing of administration remains inconclusive, earlier ingestion may shorten cecal intubation time and improve right-sided polyp detection rates.44 Other adjuncts, such as bisacodyl, lubiprostone, and mosapride, have shown limited or population-specific benefits, and dietary supplements like chewing gum or citrus extracts may enhance patient satisfaction without significantly improving bowel preparation efficacy.45-49 Based on current guidelines, the US Multi-Society Task Force conditionally recommends the adjunctive use of oral simethicone, whereas routine use of other agents is not advised due to inconsistent or low-quality evidence.6 Thus, while adjunctive agents can enhance the effectiveness and tolerability of bowel preparation, their use should be guided by patient characteristics, preparation regimen, and available evidence.
High-quality bowel preparation is a prerequisite for effective colonoscopy and plays a crucial role in the prevention of CRC. Over the past decade, low- and ultra-low-volume PEG-based solutions have significantly improved patient tolerability while maintaining effective bowel preparation. OSS and SPMC are effective alternatives for patients who cannot tolerate conventional preparations, although careful selection is warranted in the older adult or high-risk populations. Recently, the introduction of OSTs has improved patient convenience by addressing the discomfort associated with liquid-based regimens. OSTs have demonstrated better tolerability and more favorable cleansing outcomes than PEG-ascorbate, making it a valuable option for patients who struggle with large-volume preparations.
Each bowel preparation regimen has distinct advantages and limitations, highlighting the importance of individualized selection to ensure adherence and optimal mucosal visualization. The patient’s age, comorbidities, prior experience, and personal preferences should guide the choice of preparation. As bowel preparation strategies continue to evolve, clinicians must remain informed of the emerging evidence and adapt their practices accordingly. In the era of precision medicine, a patient-centered, evidence-based approach is essential for achieving optimal outcomes.
Table 1.
Multifactorial contributors to inadequate bowel preparation quality
Patient characteristics Clinical conditions Social/behavioral features
Old age (>65 years) Chronic constipation Tobacco use
Male sex Diabetes mellitus Reduced health literacy
Obesity with high body mass index (>30 kg/m2) Hypertension Low education level
Inpatient status Liver cirrhosis Low patient activation
Prior history of poor preparation Neurological conditions: stroke, Parkinson disease, dementia
Immobility
Spinal cord injury
Previous abdominal and/or pelvic surgery
Constipating medicine: tricyclic antidepressants, narcotics, opioid use
Table 2.
Comparison of bowel preparation regimens: mechanisms, volumes, efficacy, and their benefits and drawbacks
Regimen Type (mechanism) Volume Cleansing efficacy Key contraindications Special populations Benefits Drawbacks
PEG-ELS 4 L Iso 4 L High: reference standard Bowel obstruction Older adults, patients who are pregnant, IBD, R.I, ascites High efficacy; good safety profile Poor tolerability
PEG-ascorbate 2 L Iso 3 L (regimen 2 L+water 1 L) Noninferior to 4 L PEG and non-PEG regimens Bowel obstruction, G6PD deficiency, phenylketonuria, unstable angina; or acute myocardial infarction, R.I, CHF Older adults, patients who are pregnant (caution), IBD Better taste, smaller volume Risk of hemolysis in G6PD
PEG-ascorbate 1 L Iso 2 L (regimen 1 L+water 1 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, G6PD deficiency, Phenylketonuria, R.I, CHF Volume-sensitive patients; adequate hydration must be maintained. High tolerability, convenient Dehydration and hypernatremia risk in frail or older adults
Oral sulfate solution Hyper 2.9 L (regimen 0.9 L+water 2 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, R.I, CHF, ascites Young average-risk patients, patients who are pregnant (caution) Lower volume Risk of hyperuricemia and dehydration
Comparable to SPMC Hyperuricemia or Gout (caution)
Oral sulfate tablet Hyper 3 L (28 tablet+water 3 L) Noninferior to PEG (any volume); comparable to SPMC Bowel obstruction, Dysphagia, Post-bariatric surgery Tablet-tolerant patients Tablet form, High tolerability, less nausea Gastric mucosal injury risk
R.I, CHF, Ascites
Hyperuricemia or Gout (caution)
SPMC Dual 2.34 L (regimen 0.17 L+water 2 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, R.I, CHF, ascites Patients desiring taste/convenience Excellent taste Risk of hyponatremia and hypermagnesemia
Hypermagnesemia; or rhabdomyolysis.
PEG+bisacodyl Iso+stimulant 3 L (regimen 2 L+water 1 L) Comparable to 4 L PEG Bowel obstruction, CHF, older adults with vascular disease (caution) Young/healthy or prior poor prep More tolerable than 4 L PEG Rare ischemic colitis

PEG, polyethylene glycol; ELS, electrolyte lavage solution; IBD, inflammatory bowel disease; G6PD, glucose-6-phosphate dehydrogenase; R.I., renal insufficiency (creatinine clearance <30 mL/min); CHF, congestive heart failure (New York Heart Association class III or IV); SPMC, sodium picosulfate, magnesium oxide, and citric acid; PEG+bisacodyl, polyethylene glycol combined with bisacodyl; PEG+linaclotide, polyethylene glycol combined with linaclotide; Iso, iso-osmotic; hyper, hyperosmotic; dual, stimulant plus osmotic combination.

Table 3.
Patient-centered bowel preparation selection guide
Patient factors Preferred regimen(s) Agents not recommended
Age >70 years PEG-ELS, PEG-ascorbate, OSS, OST SPMC
Chronic kidney disease (eGFR <30 mL/min/1.73 m²) PEG-ELS OSS, OST, SPMC
Congestive heart failure PEG-ELS OSS, OST, SPMC
Liver cirrhosis with ascites PEG-ELS OSS, OST, SPMC
G6PD deficiency PEG-ELS PEG with ascorbate
History of gout PEG-ELS, PEG-ascorbate, SPMC OSS, OST
Dysphagia or post-bariatric surgery PEG-ELS, PEG-ascorbate OST
Pregnancy PEG-ELS, PEG-ascorbatea), OSSa) OST, SPMC
Active IBD PEG-ELS, PEG-ascorbate, OSTa) OSS, SPMC

PEG-ELS, polyethylene glycol-electrolyte lavage solution; PEG-ascorbate, polyethylene glycol combined with ascorbic acid; OSS, oral sulfate solution; OST, oral sulfate tablet; SPMC, sodium picosulfate with magnesium citrate; eGFR, estimated glomerular filtration rate; G6PD, glucose-6-phosphate dehydrogenase; IBD, inflammatory bowel disease.

a)Agents to use with caution.

  • 1. Kang MJ, Jung KW, Bang SH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat 2023;55:385–399.ArticlePubMedPMCPDF
  • 2. Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023;72:338–344.ArticlePubMed
  • 3. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658–662.ArticlePubMed
  • 4. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687–696.ArticlePubMedPMC
  • 5. Park SB, Cha JM. Quality indicators in colonoscopy: the chasm between ideal and reality. Clin Endosc 2022;55:332–338.ArticlePubMedPMCPDF
  • 6. Jacobson BC, Anderson JC, Burke CA, et al. Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 2025;168:798–829.ArticlePubMed
  • 7. Hassan C, East J, Radaelli F, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline: update 2019. Endoscopy 2019;51:775–794.ArticlePubMed
  • 8. Sinagra E, Sferrazza S, Vitello A, et al. Effectiveness and tolerability of very-low volume preparation for colonoscopy: a narrative review. Curr Drug Metab 2021;22:85–88.ArticlePubMed
  • 9. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. Gastroenterology 2014;147:903–924.ArticlePubMed
  • 10. Di Palma JA, Bhandari R, Cleveland MV, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol 2021;116:319–328.ArticlePubMedPMC
  • 11. Adamcewicz M, Bearelly D, Porat G, et al. Mechanism of action and toxicities of purgatives used for colonoscopy preparation. Expert Opin Drug Metab Toxicol 2011;7:89–101.ArticlePubMedPMC
  • 12. Enestvedt BK, Tofani C, Laine LA, et al. 4-Liter split-dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. Clin Gastroenterol Hepatol 2012;10:1225–1231.ArticlePubMed
  • 13. Spada C, Cesaro P, Bazzoli F, et al. Evaluation of Clensia®, a new low-volume PEG bowel preparation in colonoscopy: multicentre randomized controlled trial versus 4L PEG. Dig Liver Dis 2017;49:651–656.ArticlePubMed
  • 14. Kump P, Hassan C, Spada C, et al. Efficacy and safety of a new low-volume PEG with citrate and simethicone bowel preparation for colonoscopy (Clensia): a multicenter randomized observer-blind clinical trial vs. a low-volume PEG with ascorbic acid (PEG-ASC). Endosc Int Open 2018;6:E907–E913.ArticlePubMedPMC
  • 15. Barkun AN, Martel M, Epstein IL, et al. The Bowel CLEANsing national initiative: high-volume split-dose vs low-volume split-dose polyethylene glycol preparations: a randomized controlled trial. Clin Gastroenterol Hepatol 2022;20:e1469–e1477.ArticlePubMed
  • 16. Baudet JS, Castro V, Redondo I. Recurrent ischemic colitis induced by colonoscopy bowel lavage. Am J Gastroenterol 2010;105:700–701.ArticlePubMedPDF
  • 17. van Riswijk ML, van Keulen KE, Siersema PD. Efficacy of ultra-low volume (≤1 L) bowel preparation fluids: systematic review and meta-analysis. Dig Endosc 2022;34:13–32.ArticlePubMedPMCPDF
  • 18. Zhang C, Chen X, Tang B, et al. A novel ultra-low-volume regimen combining 1 L polyethylene glycol and linaclotide versus 2 L polyethylene glycol for colonoscopy cleansing in low-risk individuals: a randomized controlled trial. Gastrointest Endosc 2023;97:952–961.ArticlePubMed
  • 19. Rees DC, Kelsey H, Richards JD. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 1993;306:841–842.ArticlePubMedPMC
  • 20. Mehta JB, Singhal SB, Mehta BC. Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 1990;336:944.ArticlePubMed
  • 21. Rex DK, Di Palma JA, Rodriguez R, et al. A randomized clinical study comparing reduced-volume oral sulfate solution with standard 4-liter sulfate-free electrolyte lavage solution as preparation for colonoscopy. Gastrointest Endosc 2010;72:328–336.ArticlePubMed
  • 22. Ali IA, Roton D, Madhoun M. Oral sulfate solution versus low-volume polyethylene glycol for bowel preparation: meta-analysis of randomized controlled trials. Dig Endosc 2022;34:721–728.ArticlePubMedPDF
  • 23. Chen C, Shi M, Liao Z, et al. Oral sulfate solution benefits polyp and adenoma detection during colonoscopy: meta-analysis of randomized controlled trials. Dig Endosc 2022;34:1121–1133.ArticlePubMedPMCPDF
  • 24. Kim J, Kim HG, Kim KO, et al. Clinical comparison of low-volume agents (oral sulfate solution and sodium picosulfate with magnesium citrate) for bowel preparation: the EASE study. Intest Res 2019;17:413–418.ArticlePubMedPMCPDF
  • 25. Moulin B, Ponchon T. A comparative review of use of sulphate and phosphate salts for colonoscopy preparations and their potential for nephrotoxicity. Endosc Int Open 2018;6:E1206–E1213.ArticlePubMedPMC
  • 26. Jung Y, Kim HG, Yang DH, et al. Efficacy of oral sulfate tablet and 2 l-polyethylene glycol with ascorbic acid for bowel preparation: a prospective randomized KASID multicenter trial. J Korean Med Sci 2024;39:e301.ArticlePubMedPMCPDF
  • 27. Park JH, Hong SW, Hwang SW, et al. Efficacy and safety of oral sodium sulfate tablet compared with 1-L polyethylene glycol plus ascorbate: a prospective, randomized, endoscopist-blinded trial. J Gastroenterol Hepatol 2023;38:2090–2096.ArticlePubMed
  • 28. Song JH, Bae JH, Yim JY. Efficacy of oral sulfate tablets for bowel preparation and adenoma detection rate. J Gastroenterol Hepatol 2023;38:410–415.ArticlePubMedPDF
  • 29. Kang HS, Na SY, Yoon JY, et al. Efficacy, tolerability, and safety of oral sulfate tablet versus 2 L-polyethylene glycol/ascorbate for bowel preparation in older patients: prospective, multicenter, investigator single-blinded, randomized study. J Gastroenterol 2024;59:402–410.ArticlePubMedPDF
  • 30. Kim KO, Kim EY, Lee YJ, et al. Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: a multicentre randomized controlled study. J Crohns Colitis 2022;16:1706–1713.ArticlePubMedPDF
  • 31. Park SS, Park SC, Lee DE, et al. The risk of surgical site infection of oral sulfate tablet versus sodium picosulfate for bowel preparation in colorectal cancer surgery: a randomized clinical trial. Ann Surg Treat Res 2022;103:96–103.ArticlePubMedPMCPDF
  • 32. Villa E, Bansal M, Zakko W. S578 Oral sulfate tablet bowel preparation is associated with erosive gastritis. Am J Gastroenterol 2021;116:S263.Article
  • 33. Jeon SR, Park SK, Yang DH, et al. Comparison of a novel mini-oral sulfate tablet and the conventional oral sulfate tablet in bowel preparation for colonoscopy: a prospective, randomized, investigator-blinded, multicenter, non-inferior, phase 3 trial. J Gastroenterol 2023;58:1114–1123.ArticlePubMedPDF
  • 34. Jin Z, Lu Y, Zhou Y, et al. Systematic review and meta-analysis: sodium picosulfate/magnesium citrate vs. polyethylene glycol for colonoscopy preparation. Eur J Clin Pharmacol 2016;72:523–532.ArticlePubMedPDF
  • 35. van Lieshout I, Munsterman ID, Eskes AM, et al. Systematic review and meta-analysis: sodium picosulphate with magnesium citrate as bowel preparation for colonoscopy. United European Gastroenterol J 2017;5:917–943.ArticlePubMedPDF
  • 36. Jeon SR, Kim HG, Lee JS, et al. Randomized controlled trial of low-volume bowel preparation agents for colonic bowel preparation: 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate. Int J Colorectal Dis 2015;30:251–258.ArticlePubMedPDF
  • 37. Choi HS, Chung JW, Lee JW, et al. Polyethylene glycol plus ascorbic acid is as effective as sodium picosulfate with magnesium citrate for bowel preparation: a randomized trial. J Dig Dis 2016;17:268–273.ArticlePubMed
  • 38. Seo SI, Kang JG, Kim HS, et al. Efficacy and tolerability of 2-L polyethylene glycol with ascorbic acid versus sodium picosulfate with magnesium citrate: a randomized controlled trial. Int J Colorectal Dis 2018;33:541–548.ArticlePubMedPDF
  • 39. Bertiger G, Jones E, Dahdal DN, et al. Serum magnesium concentrations in patients receiving sodium picosulfate and magnesium citrate bowel preparation: an assessment of renal function and electrocardiographic conduction. Clin Exp Gastroenterol 2015;8:215–224.ArticlePubMedPMC
  • 40. Weir MA, Fleet JL, Vinden C, et al. Hyponatremia and sodium picosulfate bowel preparations in older adults. Am J Gastroenterol 2014;109:686–694.ArticlePubMedPDF
  • 41. Ze EY, Choi CH, Kim JW. Acute gastric injury caused by undissolved sodium picosulfate/magnesium citrate powder. Clin Endosc 2017;50:87–90.ArticlePubMedPMCPDF
  • 42. Hoy SM, Scott LJ, Wagstaff AJ. Sodium picosulfate/magnesium citrate: a review of its use as a colorectal cleanser. Drugs 2009;69:123–136.ArticlePubMed
  • 43. Moolla M, Dang JT, Shaw A, et al. Simethicone decreases bloating and improves bowel preparation effectiveness: a systematic review and meta-analysis. Surg Endosc 2019;33:3899–3909.ArticlePubMedPDF
  • 44. Wu ZW, Zhan SG, Yang MF, et al. Optimal timing of simethicone supplement for bowel preparation: a prospective randomized controlled trial. Can J Gastroenterol Hepatol 2021;2021:4032285.ArticlePubMedPMCPDF
  • 45. Theunissen F, Lantinga MA, Ter Borg PCJ, et al. Efficacy of different bowel preparation regimen volumes for colorectal cancer screening and compliance with European Society of Gastrointestinal Endoscopy performance measures. United European Gastroenterol J 2023;11:448–457.ArticlePubMedPMC
  • 46. Banerjee R, Chaudhari H, Shah N, et al. Addition of Lubiprostone to polyethylene glycol(PEG) enhances the quality & efficacy of colonoscopy preparation: a randomized, double-blind, placebo controlled trial. BMC Gastroenterol 2016;16:133.ArticlePubMedPMCPDF
  • 47. Lee J, Jeong SJ, Kim TH, et al. Efficacy of mosapride citrate with a split dose of polyethylene glycol plus ascorbic acid for bowel preparation in elderly patients: a randomized controlled trial. Medicine (Baltimore) 2020;99:e18702.ArticlePubMedPMC
  • 48. Fang J, Wang SL, Fu HY, et al. Impact of gum chewing on the quality of bowel preparation for colonoscopy: an endoscopist-blinded, randomized controlled trial. Gastrointest Endosc 2017;86:187–191.ArticlePubMed
  • 49. Kamran U, Abbasi A, Tahir I, et al. Can adjuncts to bowel preparation for colonoscopy improve patient experience and result in superior bowel cleanliness?: a systematic review and meta-analysis. United European Gastroenterol J 2020;8:1217–1227.ArticlePubMedPMCPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • Bowel preparation compliance in adult patients undergoing colonoscopy: An integrated analysis of influencing factors and advances in intervention research
      Xia Wang, Xiu-Qin Zhu, Qiao-Zhen Guo
      World Chinese Journal of Digestology.2026; 34(3): 251.     CrossRef
    • Response
      Tae-Geun Gweon
      Gastrointestinal Endoscopy.2026; 104(2): 349.     CrossRef
    • Advancing bowel preparation: DWJ1609 represents a patient-centered evolution in colonoscopy preparation
      Iyad A Issa, Taly Issa
      World Journal of Gastroenterology.2026;[Epub]     CrossRef
    • Effectiveness and safety of screening colonoscopy in adults aged 75 years and older: a retrospective cohort study from Korea
      Juyoung Lee, Mina Kim, Gwang Hyo Yim, Hyeong Ho Jo, Joong Goo Kwon, Eun Young Kim, June Hwa Bae
      Clinical Endoscopy.2026; 59(5): 843.     CrossRef
    • A real-world single-center study on the effects of low-volume polyethylene glycol electrolyte solution and rhubarb for colonoscopy preparation: quality, tolerance, and experience
      Caiwen Tan
      Frontiers in Medicine.2026;[Epub]     CrossRef
    • Impact of glucagon-like peptide-1 receptor agonists on bowel preparation quality for colonoscopy in type 2 diabetes
      Hyun Jung Park, Young Eun Oh, Sang Ah Chi, Minjee Kim, Ji Eun Kim, Sung Noh Hong, Byung-Hoon Min, Young-Ho Kim, Dong Kyung Chang, Tae-Se Kim, Eun Ran Kim
      World Journal of Gastroenterology.2026;[Epub]     CrossRef

    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Updated bowel preparation regimens for colonoscopy: benefits and drawbacks
      Clin Endosc. 2026;59(3):345-355.   Published online December 18, 2025
      Close
    • XML DownloadXML Download
    Related articles
    Updated bowel preparation regimens for colonoscopy: benefits and drawbacks
    Updated bowel preparation regimens for colonoscopy: benefits and drawbacks
    Patient characteristics Clinical conditions Social/behavioral features
    Old age (>65 years) Chronic constipation Tobacco use
    Male sex Diabetes mellitus Reduced health literacy
    Obesity with high body mass index (>30 kg/m2) Hypertension Low education level
    Inpatient status Liver cirrhosis Low patient activation
    Prior history of poor preparation Neurological conditions: stroke, Parkinson disease, dementia
    Immobility
    Spinal cord injury
    Previous abdominal and/or pelvic surgery
    Constipating medicine: tricyclic antidepressants, narcotics, opioid use
    Regimen Type (mechanism) Volume Cleansing efficacy Key contraindications Special populations Benefits Drawbacks
    PEG-ELS 4 L Iso 4 L High: reference standard Bowel obstruction Older adults, patients who are pregnant, IBD, R.I, ascites High efficacy; good safety profile Poor tolerability
    PEG-ascorbate 2 L Iso 3 L (regimen 2 L+water 1 L) Noninferior to 4 L PEG and non-PEG regimens Bowel obstruction, G6PD deficiency, phenylketonuria, unstable angina; or acute myocardial infarction, R.I, CHF Older adults, patients who are pregnant (caution), IBD Better taste, smaller volume Risk of hemolysis in G6PD
    PEG-ascorbate 1 L Iso 2 L (regimen 1 L+water 1 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, G6PD deficiency, Phenylketonuria, R.I, CHF Volume-sensitive patients; adequate hydration must be maintained. High tolerability, convenient Dehydration and hypernatremia risk in frail or older adults
    Oral sulfate solution Hyper 2.9 L (regimen 0.9 L+water 2 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, R.I, CHF, ascites Young average-risk patients, patients who are pregnant (caution) Lower volume Risk of hyperuricemia and dehydration
    Comparable to SPMC Hyperuricemia or Gout (caution)
    Oral sulfate tablet Hyper 3 L (28 tablet+water 3 L) Noninferior to PEG (any volume); comparable to SPMC Bowel obstruction, Dysphagia, Post-bariatric surgery Tablet-tolerant patients Tablet form, High tolerability, less nausea Gastric mucosal injury risk
    R.I, CHF, Ascites
    Hyperuricemia or Gout (caution)
    SPMC Dual 2.34 L (regimen 0.17 L+water 2 L) Noninferior to 4 L or 2 L PEG Bowel obstruction, R.I, CHF, ascites Patients desiring taste/convenience Excellent taste Risk of hyponatremia and hypermagnesemia
    Hypermagnesemia; or rhabdomyolysis.
    PEG+bisacodyl Iso+stimulant 3 L (regimen 2 L+water 1 L) Comparable to 4 L PEG Bowel obstruction, CHF, older adults with vascular disease (caution) Young/healthy or prior poor prep More tolerable than 4 L PEG Rare ischemic colitis
    Patient factors Preferred regimen(s) Agents not recommended
    Age >70 years PEG-ELS, PEG-ascorbate, OSS, OST SPMC
    Chronic kidney disease (eGFR <30 mL/min/1.73 m²) PEG-ELS OSS, OST, SPMC
    Congestive heart failure PEG-ELS OSS, OST, SPMC
    Liver cirrhosis with ascites PEG-ELS OSS, OST, SPMC
    G6PD deficiency PEG-ELS PEG with ascorbate
    History of gout PEG-ELS, PEG-ascorbate, SPMC OSS, OST
    Dysphagia or post-bariatric surgery PEG-ELS, PEG-ascorbate OST
    Pregnancy PEG-ELS, PEG-ascorbatea), OSSa) OST, SPMC
    Active IBD PEG-ELS, PEG-ascorbate, OSTa) OSS, SPMC
    Table 1. Multifactorial contributors to inadequate bowel preparation quality

    Table 2. Comparison of bowel preparation regimens: mechanisms, volumes, efficacy, and their benefits and drawbacks

    PEG, polyethylene glycol; ELS, electrolyte lavage solution; IBD, inflammatory bowel disease; G6PD, glucose-6-phosphate dehydrogenase; R.I., renal insufficiency (creatinine clearance <30 mL/min); CHF, congestive heart failure (New York Heart Association class III or IV); SPMC, sodium picosulfate, magnesium oxide, and citric acid; PEG+bisacodyl, polyethylene glycol combined with bisacodyl; PEG+linaclotide, polyethylene glycol combined with linaclotide; Iso, iso-osmotic; hyper, hyperosmotic; dual, stimulant plus osmotic combination.

    Table 3. Patient-centered bowel preparation selection guide

    PEG-ELS, polyethylene glycol-electrolyte lavage solution; PEG-ascorbate, polyethylene glycol combined with ascorbic acid; OSS, oral sulfate solution; OST, oral sulfate tablet; SPMC, sodium picosulfate with magnesium citrate; eGFR, estimated glomerular filtration rate; G6PD, glucose-6-phosphate dehydrogenase; IBD, inflammatory bowel disease.

    Agents to use with caution.


    Clin Endosc : Clinical Endoscopy Twitter Facebook
    Close layer
    TOP